Could Geron Corporation (GERN) See a Reversal After Breaking Its 52-Week High?

March 21, 2018 - By Louis Casey

Investors sentiment decreased to 0.97 in Q3 2017. Its down 0.24, from 1.21 in 2017Q2. It worsened, as 10 investors sold Geron Corporation shares while 27 reduced holdings. 11 funds opened positions while 25 raised stakes. 61.75 million shares or 0.63% more from 61.36 million shares in 2017Q2 were reported.
Wells Fargo & Mn owns 134,497 shares. Moreover, Prudential Incorporated has 0% invested in Geron Corporation (NASDAQ:GERN). Northern invested 0% of its portfolio in Geron Corporation (NASDAQ:GERN). Voya Invest Mngmt Ltd Liability has invested 0% in Geron Corporation (NASDAQ:GERN). Weiss Multi reported 20,000 shares. Proshare Advsr Limited Liability owns 99,896 shares for 0% of their portfolio. Assetmark Inc holds 0% of its portfolio in Geron Corporation (NASDAQ:GERN) for 335 shares. Ubs Asset Mgmt Americas Incorporated has invested 0% in Geron Corporation (NASDAQ:GERN). Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 4,723 shares. Bluecrest Management Ltd reported 0% in Geron Corporation (NASDAQ:GERN). Aperio Ltd Liability accumulated 17,744 shares. Deutsche Savings Bank Ag has 409,431 shares. King Luther Cap, a Texas-based fund reported 32,700 shares. Brave Asset Mgmt Inc has 12,900 shares for 0.01% of their portfolio. State Bank Of America De holds 0% or 95,209 shares in its portfolio.

The stock of Geron Corporation (NASDAQ:GERN) hit a new 52-week high and has $5.17 target or 7.00 % above today’s $4.83 share price. The 8 months bullish chart indicates low risk for the $776.12 million company. The 1-year high was reported on Mar, 21 by If the $5.17 price target is reached, the company will be worth $54.33 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 15.30% or $0.641 during the last trading session, reaching $4.831. About 9.46M shares traded or 194.64% up from the average. Geron Corporation (NASDAQ:GERN) has risen 13.81% since March 21, 2017 and is uptrending. It has underperformed by 2.89% the S&P500.

Geron Corporation (NASDAQ:GERN) Ratings Coverage

Among 3 analysts covering Geron (NASDAQ:GERN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Geron had 7 analyst reports since August 8, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 10 by MLV. The firm has “Hold” rating by Stifel Nicolaus given on Tuesday, August 1. On Monday, December 7 the stock rating was maintained by Piper Jaffray with “Overweight”. The firm earned “Outperform” rating on Tuesday, September 13 by FBR Capital. The stock has “Hold” rating by Zacks on Saturday, August 8. On Monday, March 19 the stock rating was maintained by Piper Jaffray with “Buy”. As per Sunday, March 18, the company rating was maintained by Stifel Nicolaus.

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $776.12 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.